NKTR Stock Surged To Over Four-Year Highs Today – What’s Driving The Rally?

• Data from the study of Nektar’s investigational therapy, Rezpegaldesleukin, showed patients achieving meaningful hair growth.
• The firm stated that 94% of participants completed the full treatment period.
• Separately, initial data from a Phase 2 study in Stage 3 new-onset Type 1 diabetes is expected in 2027. 

Nektar Therapeutics (NKTR) generated significant retail buzz on Monday morning as the stock surged 18% after the biotech firm reported encouraging 52-week topline results from its mid-stage trial for patients with severe alopecia areata, a chronic autoimmune disease that leads to hair loss.

NKTR shares traded at their highest levels in more than four years. The stock was placed under a trading halt for 40 minutes earlier in the day.

Meanwhile, retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.

Rezpegaldesleukin Treatment Shows Meaningful Hair Growth

Data from a 92-patient study of Nektar’s investigational therapy, Rezpegaldesleukin, showed continued improvement in hair regrowth after 52 weeks of treatment, with about 29% to 31% of patients in higher-dose groups achieving significant scalp hair coverage.

The treatment was generally well tolerated, with most side effects being mild, and no patients stopped therapy due to safety concerns. Notably, 94% of participants completed the full treatment period.

Nektar plans to submit the REZOLVE-AA trial results for presentation at a medical conference in 2026.

The U.S. Food and Drug Administration (FDA) granted Fast Track designation to Rezpegaldesleukin in 2025 for the treatment of atopic dermatitis and alopecia areata in patients aged 12 and older. The drug is being developed as a self-administered injection for several autoimmune diseases, including Type 1 diabetes.

Pipeline Watch

Last month, the company announced plans to begin Phase 3 trials in the third quarter (Q3) of 2026 for patients with moderate-to-severe atopic dermatitis. Topline data from a 24-week off-treatment period in the REZOLVE-AA study is expected in the fourth quarter of 2026, and results from a longer 52-week off-treatment period in the REZOLVE-AD study are anticipated in the first quarter (Q1) of 2027.

Additionally, initial data from a Phase 2 study in Stage 3 new-onset Type 1 diabetes, sponsored by TrialNet, is expected later in 2027.

Year-to-date, the stock has gained more than 120%.

Read also: CADL Stock Gets A Bullish Call Just Weeks Before Crucial Prostate Cancer Data Reveal

For updates and corrections, email newsroom[at]stocktwits[dot]com.